艾曲泊帕联合地塞米松一线治疗新诊断成人免疫性血小板减少症的疗效与安全性
XPAG-ITP试验比较艾曲泊帕联合地塞米松与地塞米松单药一线治疗新诊断成人免疫性血小板减少症。联合组在缓解持续时间和补救用药使用方面呈现质量上的优势,且持续缓解者基线T细胞克隆性较高。
要点
- 艾曲泊帕联合地塞米松一线治疗可延长缓解持续时间并减少补救用药。
- 持续缓解者基线T细胞克隆性高,提示免疫应答差异。
- 艾曲泊帕起始50 mg/日,未达目标血小板计数可增量25 mg。
核心结论
- 艾曲泊帕联合地塞米松一线治疗新诊断成人ITP在缓解持续时间和补救用药使用上呈现质量上的优势。
- 持续缓解者与未缓解者的T细胞免疫应答不同,持续缓解者基线T细胞克隆性高。
研究设计与样本
- XPAG-ITP试验,将新诊断成人ITP患者随机分配至地塞米松单药组或艾曲泊帕联合地塞米松组。
主要发现
- 联合组患者呈现质量上更长的缓解持续时间。
- 联合组患者呈现质量上减少的补救用药使用。
- 持续缓解者基线T细胞克隆性高,克隆以气泡图右侧表示。
关键数值与推荐
- 地塞米松单药组:地塞米松40 mg/日,第1-4天,每28天一个周期,1至3个周期,最长12周,第2和第3周期可选。
- 联合组:艾曲泊帕联合第1天开始的地塞米松40 mg/日第1-4天短程。
- 艾曲泊帕起始剂量50 mg/日持续2周,未达目标血小板计数≥50×10^9/L者增量25 mg。
- 艾曲泊帕减量:每2周减25 mg至最低剂量25 mg隔日一次。
临床怎么用
- 对新诊断成人ITP可考虑艾曲泊帕联合地塞米松作为一线治疗选项。
- 治疗中目标血小板计数为≥50×10^9/L,未达标时艾曲泊帕可增量25 mg。
- 艾曲泊帕减量按每2周减25 mg至25 mg隔日一次进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Left panel: Scheme of the XPAG-ITP trial. The dexamethasone monotherapy (DEX) arm consisted of DEX 40 mg/day for days 1-4 for one to three cycles every 28 days to a maximum of 12 weeks, cycles 2 + 3 were optional. Patients randomised to eltrombopag combined with dexamethasone (ETB + DEX) received eltrombopag (ETB) in combination with a short course of high-dose DEX beginning on day 1 (40 mg/day during days 1-4). The starting dose of ETB was 50 mg/day for 2 weeks; thereafter, the ETB dose was increased by 25 mg for all patients who did not achieve the target platelet count of ≥50 × 109/L. The ETB tapering was performed by decreasing the dose by 25 mg every 2 weeks to a minimum dose of 25 mg every other day for all patients. Right upper panel: Clinical outcomes in patients treated with first-line ETB + DEX. Patients displayed a qualitatively longer response duration and qualitatively reduced usage of rescue medication. Right lower panel: The immunological T-cell response was different in treatment responders and non-responders. Patients with sustained response (responders) displayed a high T-cell clonality at baseline. Clones are depicted as bubbles (right side).
引用
- Jauch AJ, Schmidt-Barbo P, Schultheiss C, et al. Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia. Br J Haematol. 2026. PMID: 41496604. doi:10.1111/bjh.70312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。